Nutriband Inc. announced that the United States Patent and Trademark Office issued a patent on June 3, 2025, for its "Abuse and Misuse Deterrent Transdermal Systems." This patent expands the company's intellectual property protection for its abuse deterrent transdermal products, which utilize proprietary Aversa™ technology to prevent the misuse and diversion of drugs with abuse potential. The Aversa™ technology is covered by an extensive international patent portfolio with patents in 46 countries. Nutriband's lead product under development is Aversa™ Fentanyl, an abuse deterrent fentanyl transdermal system.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.